Your session is about to expire
← Back to Search
Magnetic Tracer
FerroTraceTM for Colorectal Cancer
Phase 1 & 2
Waitlist Available
Led By George Chang
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new method using magnetic particles and green dye to find important lymph nodes in patients with colorectal cancer. The goal is to improve detection of cancer spread and ensure safety by monitoring any side effects.
Eligible Conditions
- Colorectal Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: FerroTraceTM (magnetic tracer)Experimental Treatment2 Interventions
a special type of fluorescent dye called indocyanine green (ICG) during surgery can help surgeons find the lymph nodes that the cancer is most likely to have spread to in colorectal cancer patients.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
indocyanine green (ICG)
2019
Completed Phase 3
~20
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,054 Previous Clinical Trials
1,798,884 Total Patients Enrolled
George ChangPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
120 Total Patients Enrolled
Matthew TillmanPrincipal InvestigatorM.D. Anderson Cancer Center
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger